comprehensive -WSS

comprehensive

author：comprehensive 2025-09-29 22:47:30 - browse：3945

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： UnitedHealth sued over use of algorithm in Medicare Advantage plans

hotspot

WSS

How state and local governments are sidelining science

Why are elite athletes different? Take a look at their microbes

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Disclosing genetic information: not as worrisome as once feared

Wikipedia

comprehensive

knowledge

Medical records are filled with copy

Ask STAT: What do you want to know about ChatGPT in medicine?

Walensky prepares to leave CDC — and Congress — behind

What health policies could hitch a ride on a spending bill?

Peter Hotez and the public health issue of online harassment

Type 2 diabetes prevention programs work at large scale: study

Supreme Court strikes down use of affirmative action

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Guidelines to prevent youth baseball injuries need more muscle

What health policies could hitch a ride on a spending bill?

knowledge

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

The battle over the Brookhaven Landfill on Long Island

3 hurdles to bringing medical devices to the U.S. market

Experimental asthma app from Apple and Anthem shows promise

Do masks work? RCTs can't tell us

White House drug czar issues call for 'recovery

hotspot

focus

focus

leisure time